1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Ergot Alkaloids (Migraine) - Forecast and Market Analysis to 2023

  • March 2014
  • 47 pages
  • GlobalData
Report ID: 2114395

Summary

Table of Contents

Ergot Alkaloids (Migraine) - Forecast and Market Analysis to 2023

Summary

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

The Ergot Alkaloids were the very first anti-migraine-specific therapy class to reach the market. The first pure ergot alkaloid was isolated in 1920, but only in 1925 was ergotamine used to successfully treat a case of severe and intractable migraine via subcutaneous injection (Rothlin, 1955; Stoll, 1965). Over the following decades, ergotamine’s use as a migraine treatment was investigated by various researchers and its potent vasoconstriction properties reinforced the belief that migraine had a vascular origin.

Scope

- Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Ergot Alkaloids including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Ergot Alkaloids for the top two countries from 2012 to 2023.
- Sales information covered for the US and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Migraine
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Ergot Alkaloids performance
- Obtain sales forecast for Ergot Alkaloids from 2012-2023 in the top two countries (the US and Japan)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Global Pain Management Drugs Market: Analysis By Type (Opioids, NSAIDs, Anti-Migraine, Anticonvulsants), By Application, By Region, By Country: Opportunities and Forecast (2011-2021)

  • $ 2400
  • Industry report
  • May 2017
  • by Azoth Analytics

Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report titled “Global ...

Eletriptan Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Eletriptan Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Eletriptan worldwide and by countries in North America, Europe, Japan, BRIC, ...

Naproxen / Sumatriptan Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Naproxen / Sumatriptan Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Naproxen / Sumatriptan worldwide and by countries in North America, ...


Download Unlimited Documents from Trusted Public Sources

Opioid Market in the US

  • May 2017
    9 pages
  • Opioid  

    Analgesic  

  • United States  

View report >

Therapy Market in the US

  • April 2017
    44 pages
  • Therapy  

    Serotonin Speci...  

    Antidepressant  

  • United States  

View report >

Analgesic Market in South Africa

  • April 2017
    7 pages
  • Analgesic  

  • South Africa  

View report >

Anti-infective Market

6 months ago

Related Market Segments :

Antimigraine
Therapy
Pain Relief

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.